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Abstract
Background: Since 2007, a Human Papillomavirus (HPV) vaccination programme against cervical cancer (CC) is
implemented in Italy in 11-year-old girls. The extension of HPV vaccination to young adult women, or to 11-year-old
boys could further reduce the CC burden, in the latter case from indirect effect on HPV transmission. The objective of
the study was to compare the potential CC cases prevention from HPV-16/18 AS04-adjuvanted vaccination of adding
catch-up targeting 15- or 25-year-old girls to the addition of boys vaccination in Italy.
The models assessing the impact of these alternative vaccination strategies are usually dynamic models requiring
numerous input data. Simpler models could however provide some insight into this question, as reported in the
current study.
Methods: A published cohort model adapted to the Italian setting was used to estimate the potential CC reduction
following different HPV vaccination strategies with a HPV-16/18 AS04-adjuvanted vaccine: vaccination of 11-year-old
girls, female aged 15 or 25 years. The model assumed that the maximum benefit obtained from vaccinating boys
equals the CC reduction that would result from immunisation of all non-vaccinated girls of the same age. Each
cohort of 11-year-olds (either girls or boys) was assumed to include 281,000 individuals and a 70 % vaccination
coverage was applied. Sensitivity analysis was performed by varying the vaccination coverage and the overlap in
potential sexual contacts between vaccinated boys and girls of the same age-group.
Results: Under base case, compared with the screening-only scenario, HPV vaccination of 11-year-old girls,
15-year-old females, 25-year-old females or 11-year-old boys, would prevent 1,146, 1,082, 788 or 491 CC cases
respectively. HPV vaccination of boys could result in more CC cases prevented than adding a female catch-up
only in scenarios with low vaccination coverage in the primary target cohort and when combined with small
overlap between vaccinated boys and girls of the same age cohort.
Conclusions: For a fixed limited additional budget allowing the inclusion of a single catch-up cohort, the
extension of HPV vaccination to girls or young women instead of boys was estimated to maximise the number of
CC cases prevented.
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Background
High-risk Human Papillomavirus (HPV) is the causal
agent of cervical cancer (CC) [1, 2]. The persistent onco-
genic HPV infection is the first step for the development
of cervical precancerous lesions and, subsequently, of
CC [3]. Oncogenic HPVs are also responsible for other
anogenital cancers (primarily vagina, vulva, anus and
penis) and their aetiological role, although with a lower
attributable risk, has also been confirmed in head and
neck cancers [4, 5].
According to data reported by the International
Agency for Research on Cancer (IARC), CC is the fourth
most common cancer in women in the world, and the
seventh overall, with an estimated 527,624 new cases in
2012. In the same year, in the European Union, the
IARC estimated 33,679 incident cases, 13,136 deaths,
and the 5-year prevalence was 115,283 cases [6].
In Italy, CC was the fourth most frequent tumour in
females aged 0–49 years in 2011 (6 % of overall inci-
dence in the specific age-group). Although the incidence
rate of CC showed a statistically significant reduction
between 1998 and 2005, the mortality rate had a steady
trend over the same period [7]. According to 9 Italian
cancer registers, during the 2005–2009 period, 222 new
CC cases were notified each year in Italy [7]. Other data
from the Istituto Superiore di Sanità show that, for the
1998–2002 period, around 3,500 CC cases were diag-
nosed every year in Italy [8].
Two vaccines against HPV infection (a HPV-16/18
AS04-adjuvanted and a HPV-6/11/16/18 vaccine) are
currently available in Italy and are used for the
prevention of CC. Both vaccines have confirmed ability
to reduce infection and precancerous lesions caused by
HPV-vaccine types in a naïve girls population [9, 10].
The HPV-16/18 AS04-adjuvanted vaccine has also
shown cross-protective efficacy against 4 oncogenic
non-vaccine HPV types (HPV-33/31/45/51), possibly
due to the presence of the AS04 Adjuvant System in the
vaccine formulation, which enhances the overall immune
response [11] as further confirmed by the 93 % overall
efficacy shown against cervical intraepithelial neoplasia
(CIN) grade 3+ lesions at year 4 of follow-up irrespective
of HPV subtype [12]. The HPV-6/11/16/18 vaccine also
has shown cross-protection versus HPV-31 although to
a lesser extent [13, 14]. In Europe, the HPV-6/11/16/18
vaccine was granted an indication for boys vaccination
in 2014 [15]. To date, the HPV-16/18 AS04-adjuvanted
vaccine has no indication for boys; however, a clinical
study has demonstrated immunologic response among
boys similar to the one observed among girls [16, 17].
In Italy, HPV vaccination is actively offered free of
charge to 11-year-old girls since 2007–2008 (depending
on the region). In addition, some Italian regions have ex-
tended active offer to older female age-groups: 3 regions
to girls aged 15 years, 4 regions to girls aged 16 years, 3
regions to young women aged 18 years and 1 region to
young women aged 25 years (adopting a simultaneous
4-cohort strategy). In some regions, free-of-charge
immunisation is maintained for some years after
including an age cohort as target, and a co-payment
system is foreseen in the other cohorts not included in
the target age-cohort. In 2007, the coverage objective of
the universal HPV immunisation programme was >95 %
with 3 vaccine doses in 11-year-old girls, within 5 years
from start. In the new Italian National Vaccination Plan
(2012–2014), the coverage target was modified because of
the difficulty in the achievement of the initial objective,
with an adjusted 3-dose coverage of ≥70, ≥80 and ≥95 %
in the 2001, 2002, and 2003 birth cohorts, respectively. At
the end of 2012, a 70 % vaccination coverage with 3
doses of HPV vaccine was achieved in only 12, 10 and
8 Italian regions for the 1997, 1998 and 1999 birth co-
horts respectively. Therefore, 5 years after the start of
the immunisation programme against HPV in Italy, the
vaccination coverage in the target population did not
show the expected increase [18–20].
A larger impact of HPV vaccination could be reached by
improving coverage among targeted girls, but alternative
or additional approaches could also be sought. The
addition of girls catch-up age-groups could be of benefit
[21] but questions remain about the benefit of vaccinating
boys [22].
Health authorities are currently questioning how the
adoption of catch-up programmes in older age-cohorts
of girls may compare with vaccination of boys, in
addition to the efforts to increase vaccination coverage
in the primary target group, in order to maximise CC
prevention. As reported by the European Centre for
Disease Prevention and Control (ECDC) in its last
document ‘Introduction of HPV vaccines in European
Union countries–an update’, the decisions to recom-
mend the vaccine for boys and/or men depend on
the epidemiology of HPV-related diseases in a specific
country, the cost-effectiveness, and the affordability of
the vaccine [23]. Therefore, the evaluation of the ex-
pected clinical outcomes resulting from the adoption
of different vaccination scenarios involving “girls only”
or “boys and girls” could help answer that question.
Most models addressing this question are dynamic
models requiring many input data limiting their adap-
tations to a few country settings, but also reducing
transparency, hence making the evaluation of the
model challenging [22].
Based on a simplified model, the objective of our
analysis was to compare the potential additional
number of CC cases avoided using the HPV-16/18
AS04-adjuvanted vaccine through different catch-up
vaccination scenarios of older girls, or the vaccination of
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boys added to the vaccination of a first cohort of girls in
Italy.
Methods
This analysis uses the output of a published Markov
model adapted to the Italian setting to estimate the CC
reduction expected from different catch-up scenarios
added to the primary target vaccination (15 or 25 years
of age to cover the range of girls included in catch-up
scenarios [24]), as well as the maximum potential effect
of adding the vaccination of boys to the vaccination of
girls (11 years of age) in terms of number of CC pre-
vented at the country level, the ultimate aim of HPV
vaccination [25, 26].
Model description and input data
The analyses were conducted using an existing lifetime
Markov cohort model developed in Microsoft Excel and
adapted to the Italian setting [25]. The model has a 1-year
cycle over 95 cycles (lifetime) to capture the entire poten-
tial effect of the vaccine. It reproduces the natural history
of oncogenic HPV as well as the effect of screening and
vaccination with 12 health states (healthy, oncogenic
HPV infection, CIN1, CIN2/3, persistent CIN2/3, CC,
CC cured, CC deaths, other deaths, CIN1 detected by
screening, CIN2/3 detected by screening and persistent
CIN2/3 detected by screening). The transition probabil-
ities used to reproduce the progression and regression
from healthy, to HPV infection, to lesion were retrieved
from the literature (Table 1). Given the severity of the
disease, limited data are available on the entire natural his-
tory of HPV disease. Lesions are treated upon detection to
prevent further progression of the disease. No single study
therefore reports all progression and regression rates
needed to populate the model. Hence, multiple
sources had to be used as generally used for similar model
calibration [27–31]. Screening allows detecting lesions
that can then be treated and potentially cured.
Vaccination was assumed to reduce the transition
from healthy to oncogenic HPV infection (hence
reducing all subsequent HPV-related lesions) as of the
age at vaccination. Therefore, the model assumes no
effect of the vaccine on pre-existing infections or
lesions that will continue to evolve according to the
natural history. This allows estimating the effect of
vaccinating girls after sexual debut [26].
The vaccine effect is based on the expected effectiveness
on CC. The prevention of CIN1 and CIN2/3 is however
expected to be lower than the prevention of CC. The
number of CIN1 and CIN2/3 post-vaccination were there-
fore adjusted according to the difference between the
effectiveness on CC and the respective effectiveness on
CIN1 and CIN2/3. Vaccine efficacy observed at year 4 of
follow-up on the lesion irrespective of HPV types in the
HPV-16/18 AS04-adjuvanted vaccine PATRICIA trial
(NCT00122681) was used as a proxy of vaccine effectiveness
at all ages (Table 1). It was therefore assumed that this
observed efficacy applies to the Italian setting. A lifetime
protection of the vaccination was assumed. The size of the
11-year-old girls cohort modelled was set at 281,000,
based on the current demography in Italy (Table 1). The
same size per age was assumed for a cohort of boys. All
input data and assumptions included in the model are
shown in Table 1.
Model output
The incidence of CC cases over the lifetime of the co-
hort associated with different vaccination strategies was
calculated by the model under 4 different scenarios:
 CC screening only
Table 1 Input data in the mathematical model
Parameter Value References
Vaccination Cohort size 281,000 [53]
Global vaccine efficacy CC
(proxy CIN3+)
93 % [12]
Global vaccine efficacy CIN2/3
(proxy CIN2+)
65 % [12]
Global vaccine efficacy CIN1
(proxy CIN1+)
50 % [12]
Age at vaccination 11, 15 or
25 years
Assumed
Vaccine waning None Assumed
Screening Screening age range 25 to
64 years
[32]
Screening interval every
3 years
[32]
Percentage screened 65 % [32]
Percentage never screened 35 % [32]
Cytology sensitivity 58–61 % [54]
Compliance to CIN 1
treatment
37 % [32], expert
opinion
Compliance to CIN 2/3
treatment
100 % [32], expert
opinion
Efficacy of CIN treatment 90 % [32], expert
opinion
Transition
Probabilities
Healthy to HPV 0.07 [55]
HPV to CIN 1 0.05 [56]
CIN 1 to CIN 2/3 0.09 [57–59]
CIN 2/3 to persistent CIN 2/3 0.11 [57, 59]
HPV clearance to healthy 0.45 [60–64]
CIN 1 clearance 0.24 [57–59]
CIN 2/3 clearance 0.23 [57, 59]
Persistent CIN 2/3 to CC 0–0.06 Calibrated
CC cervical cancer, CIN cervical intraepithelial neoplasia, HPV
Human Papillomavirus
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 CC screening and 100 % vaccination of females at
the age of 11 years (primary vaccination target)
 CC screening and 100 % vaccination of females at
the age of 15 years (15-year-old catch-up cohort)
 CC screening and 100 % vaccination of females at
the age of 25 years (25-year-old catch-up cohort).
CC screening was assumed to take place every 3 years
between the age of 25 and 64 years, and to cover 65 %
of the female population [32]. These scenarios were used
to estimate the lifetime number of CC cases remaining
under the different vaccination coverage by calculating a
weighted average of expected lifetime CC for strategies
with and without vaccination (i.e. for a 30 % coverage,
the lifetime CC were estimated by adding 70 % without
vaccination and 30 % with vaccination). In the base case
evaluation, HPV immunisation was assumed to cover
70 % of the vaccinated cohort.
Estimation of the impact of vaccinating 11-year-old boys
The effect of boys vaccination, investigated in our evalu-
ation, is estimated indirectly. The assumption taken is
that the maximum benefit of boys vaccination would be
to prevent the cervical cancers that are not already
directly prevented by the girls vaccination. The impact
of boys is therefore not derived from a potential efficacy
on boys but well on the maximum expected impact on
girls.
To estimate the potential CC reduction associated
with vaccinating a 11-year-old boys cohort, it was as-
sumed that the resulting maximum reduction in CC
cases would correspond to the maximum expected re-
duction in CC cases of non-vaccinated 11-year-old girls
as if they were all vaccinated. The reduction in the CC
incidence from a 11-year-old boys vaccination, therefore,
corresponds to the difference between the number of
CC cases avoided under a 100 % vaccination coverage of
a 11-year-old girls cohort and the number effectively
prevented under the real vaccination coverage (i.e.
70 %). It was therefore assumed that the vaccination of
boys would only lead to reduction in CC cases in the
same age-group of females. This is schematically pre-
sented in Fig. 1.
Sensitivity analysis
A one-way sensitivity analysis was conducted on the
lifetime number of CC prevented under different
vaccination coverage of both boys and girls. Two-way
sensitivity analysis on lifetime CC incidence, accounting
for a change in the vaccination coverage and the vac-
cination mismatch between vaccinated boys and girls
was also performed. Specific sensitivity analyses of the
duration of protection and cross-protection were also
investigated.
Vaccination coverage among the catch-up cohorts
The vaccination coverage among the different scenarios
was varied from 20 to 100 %. Under each scenario and
coverage rate, the number of CC potentially prevented
was estimated.
Vaccination mismatch between vaccinated boys and girls
The vaccination of boys can result in CC prevented
only if vaccination of boys allows preventing CC among
non-vaccinated girls. The mismatch factor allows taking
into account the portion of the non-vaccinated girls
protected by boys vaccination. It was ranged from
100 %, corresponding to the maximum benefit (i.e. the
boys vaccination protects all non-vaccinated females),
to 0 %, corresponding to the minimum benefit (i.e. the
boys vaccination does not protect any of the non-
vaccinated females as a result of exclusive interaction
with vaccinated women).
Vaccine cross-protection and duration of protection
The impact of a reduced vaccine cross-protection or
duration of protection on the results was investigated.
The vaccination coverage in a girls catch-up programme
below which the boys vaccination strategy (assuming
maximum expected benefit from boys vaccination) is
modelled to lead to more CC prevented than the
addition of a catch-up programme was estimated for dif-
ferent vaccine efficacy and vaccine duration of protec-
tion. Vaccine efficacy was ranged using the observed
95 % confidence interval around average vaccine efficacy,
irrespective of HPV type. The duration of protection
was set at 10, 20 and 30 years assuming no booster.
Results
Model output
The remaining lifetime incidence of CC cases with or with-
out the adoption of a HPV vaccination programme among
females, in each analysed female cohort, as predicted by the
model for a 100 % vaccination coverage, is presented in
Fig. 2. These results are used as input data to the assess-
ment model allowing the estimation of the CC cases under
the different vaccination coverage and the maximum im-
pact of boys vaccination.
HPV vaccination can only prevent incident infections.
It is assumed to have no effect on the natural history of
infections acquired before vaccination. As a result, the
number of lifetime CC cases decreases between the sce-
nario “screening only”, to vaccination at ages of 25, 15
and 11 years. The lifetime incident CC cases ranges from
1,785 CC for screening only to 148 CC for a 11-year-old
girls vaccination, per cohort.
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Base case results
The number of CC cases prevented under the base case
vaccination strategies (primary vaccination, catch-up co-
horts and boys vaccination) is presented per cohort in
Table 2.
The maximum reduction of incident CC cases is obtained
with the vaccination of the primary cohort (11-year-old
girls), followed by a catch-up of a cohort of 15-year-old girls,
then a catch-up of 25-year-old women. The vaccination of
boys is expected to lead to the smallest reduction of CC.
Sensitivity analysis
Results of the one-way sensitivity analysis on the lifetime
incidence of CC cases prevented are presented in Fig. 3
and the two-way sensitivity analysis in Fig. 4.
Figure 3 reports the lifetime incident CC cases pre-
vented for the catch-up vaccination scenarios and the
vaccination of the 11-year-old boys for varying vaccination
coverage for the catch-up cohorts, while assuming 70 % of
the 11-year-old girls are covered. The vaccination of boys
is predicted to result in more CC cases prevented than a
catch-up cohort only for a vaccination coverage lower
than 31 % for a catch-up of 15-year-old girls, and lower
than 43 % for a catch-up of 25-year-old women.
Figure 4 reports the results of the two-way sensitivity
analysis on the lifetime incidence of CC cases prevented
among the 11-year-old cohort for both boys and girls
strategies under different vaccination coverage for the 11-
year-old girls or boys, and 3 scenarios (100, 50 and 0 %)
for the mismatch between the vaccinated boys and girls.
The mismatch significantly impacts on the number of
CC cases potentially prevented by the adoption of boys
vaccination. Boys immunisation could lead to larger ben-
efits for a vaccination coverage among girls lower than
Fig. 1 Schematic vaccination pattern investigated for a 11-year-old girls or boys cohort and resulting outcomes. Legend: NC not covered; 30 % of
the cohort not directly protected by the vaccine, SI successfully immunised; 70 % of subjects directly protected by the vaccine
Fig. 2 Lifetime incident cervical cancer cases per each cohort of 281,000 females under different prevention strategies targeting females
(screening: 65 % screened every 3 years from 25 to 64; vaccination: 100 % vaccination coverage) used as input to the assessment model. Legend:
CC cervical cancer
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50 % with a 100 % mismatch and 34 % with a 50 % mis-
match. A 0 % mismatch could result, however, in no
additional CC prevented from boys vaccination.
The vaccination coverage in a catch-up programme at
which boys vaccination would lead to more CC prevented
than the addition of a catch-up programme is reported in
Table 3 under different vaccine profiles regarding the
overall efficacy or the duration of protection.
Discussion
Achieving high HPV vaccination coverage in the primary
target group (11-year-old girls) is the top priority concerning
HPV immunisation programmes in all developed coun-
tries for a number of reasons: vaccination before the
sexual debut maximises the impact of immunisation;
pre-adolescents show an excellent immunological
response to HPV vaccines; therefore, also from an eco-
nomic point of view, 11-year-old girls immunisation is
the most effective option. However, in Italy, HPV
vaccination coverage did not reach the foreseen 95 %
coverage objective yet.
A better impact of HPV vaccination on the incidence
of CC cases could be achieved with the addition of a co-
hort of vaccinated females in the age range of 15–25
years. The adoption of a multi-cohort strategy might
protect age-groups that are entering or are already at
risk of incident HPV infection. This kind of preventive
intervention (active and free-of-charge offer to second-
ary age-groups) is already adopted in some Italian re-
gions (Valle d’Aosta, Piemonte, Liguria, Trentino-Alto
Adige, Friuli-Venezia Giulia, Toscana, Marche, Basilicata
and Puglia).
Another possible prevention strategy could be the ex-
pansion of HPV vaccination to 11-year-old boys, in
addition to the primary girls vaccination. In fact, some
Italian regions have already introduced active free-of-
charge HPV vaccination of males (Veneto, Liguria,
Friuli-Venezia Giulia, Puglia, Sicilia and Basilicata).
Recently, some other countries, like USA and Canada,
also included HPV vaccination of boys in immunisation
programmes. As a matter of fact, the American Centers
for Disease Control and Prevention (CDC) recommended
that both young boys and girls should be vaccinated
against HPV because of disappointing coverage rate in
girls reached in the last years (49 % of adolescent girls
received at least the first of the 3 doses of HPV vaccine
in 2010). Vaccination of males would likely reduce HPV
transmission, and resulting infection, disease, and can-
cers in females (through herd immunity) [33, 34]. How-
ever, very few adolescent males received the HPV
vaccine during the first year following its recommenda-
tion for this gender in the USA. Therefore, in order to
Table 2 Cervical cancer averted under the base case
vaccination strategy for each targeted cohort separately
Vaccination strategies Cervical cancer prevented
vs. screening only
Primary vaccination
70 % 11-year-old girls
vaccinated
1,146
Catch-up programmes
70 % 15-year-old girls
vaccinated
1,082
70 % 25-year-old women
vaccinated
788
Boys vaccination (maximum potential benefit among 11-year-olds)
70 % 11-year-old boys
vaccinated
491
Fig. 3 One-way sensitivity analysis on the lifetime incident cervical
cancers prevented for a range of vaccination coverage for the
catch-up cohorts. Legend: CC cervical cancer
Fig. 4 Two-way sensitivity analysis on the lifetime incident cervical
cancers prevented for a range of vaccination coverage for the
primary cohort and mismatch factor. Legend: CC cervical cancer
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reach high vaccination coverage in boys, compliance of
adolescent males and their parents should be improved
[35, 36]. A widespread acceptance by recipients and
parents is a key point for the successful implementation
of the HPV vaccination programme. According to a
systematic review, the current low coverage of HPV im-
munisation by active offer is due to: scarce knowledge
of HPV and the HPV vaccines; high costs in countries
where these costs are incurred by the recipient or his/
her parents; perceived low efficacy of the vaccine; and
alleged and real adverse events to HPV vaccines [37].
However, females perceive the greatest health benefit
through HPV immunisation (avoidance of CC), with a
better acceptance of vaccination. This perception of
health gain is less evident in males, and the introduc-
tion of boys vaccination to coverage levels similar to
those achieved in females might be very difficult to
reach.
In many European countries, as in Italy, coverage rates
of girls immunisation reached lower levels than ex-
pected, despite the relevant efforts made by health au-
thorities [38]. The most effective strategy to prevent
HPV-related morbidity could be universal immunisation
as the inclusion of boys in the current HPV vaccination
programme is likely to be beneficial to both sexes: boys
immunisation, in addition to indirectly protecting cancer
in girls, is directly effective in the prevention of HPV-
related conditions in men (such as anal cancer). In
addition, despite the clinical benefits of universal
vaccination, the immunisation programmes including
boys in the current HPV vaccination strategies are pres-
ently not considered a priority. From this point of view,
the ECDC position expressed in the recent guidance re-
lated to the introduction of HPV vaccines in European
Union countries (2012) suggests that universal
immunisation programmes for boys seem to be too costly
compared to the potential benefits [38]. These evaluations
were based on the results of dynamic models.
We developed a simpler model to estimate the po-
tential relative efficiency of immunisation on CC, com-
paring boys HPV vaccination with a catch-up HPV
vaccination programme in older adolescents and young
women. A series of assumptions had therefore to be
made. The indirect efficacy of boys vaccination on CC
is unknown. We did therefore make assumption by es-
timating that the maximum benefit of boys vaccination
would result from prevention of CC among girls in the
same age-group. However, boys vaccination could
benefit younger or older girls or on the contrary pro-
tect a limited number of girls in the same age-group.
The exact proportion of non-vaccinated girls that
could be protected is therefore difficult to exactly
measure. A potential weakness of our study is that it
only focuses on the prevention of CC, which, however,
represents the major HPV-related burden in cancer
cases. Nevertheless, the approach of our model could
be extended to other HPV-related diseases. In that
case, additional assumptions would need to be taken
into account for the potential direct and indirect pro-
tection afforded by immunisation from either boys or
girls vaccination.
The results of our analysis suggest that the vaccination
of an additional cohort of 15- or 25-year-old females in a
catch-up programme would save a larger number of CC
cases than an immunisation programme also for 11-
year-old boys. The vaccination of boys with HPV vac-
cine was estimated to result in a larger CC reduction
than a catch-up programme in young adult women
only in a scenario of low vaccination coverage in the
primary target, which is not currently the case in Italy.
Therefore, in a setting with relatively high vaccination
coverage among 11-year-old girls, adding a catch-up
vaccination programme among older girls would pre-
vent more CC cases than adding boys vaccination. The
model also highlights the importance of overlap be-
tween vaccinated boys and girls: a 0 % mismatch
between vaccinated boys and vaccinated girls corre-
sponding to all vaccinated girls being in contact with
the vaccinated boys only, could result in no additional
benefit from boys vaccination. The maximum benefit
from boys vaccination appears when 100 % mismatch
exists between the two vaccinated groups. This corre-
sponds to boys mixing with unvaccinated girls, hence
all unvaccinated girls would indirectly be protected by
boys vaccination.
In relative terms, these results are insensitive to the
vaccine efficacy. Indeed, a change in the vaccine efficacy
does impact the overall expected reduction in CC cases
Table 3 One-way sensitivity analysis on the vaccination
coverage below which a full boys vaccination leads to more
cervical cancer cases prevented than a catch-up vaccination
Vaccination coverage
Parameter varied in the
sensitivity analysis
15-year-old girls
catch-up
25-year-old women
catch-up
% coverage
(N girls)
% coverage
(N girls)
Base case (VE 93 %, lifetime
duration of protection)
31 % (87,110) 43 % (120,830)
VE = 79 % 31 % (87,110) 43 % (120,830)
VE = 99 % 31 % (87,110) 43 % (120,830)
Vaccine duration of
protection = 10 years
27 % (75,870) 30 % (84,300)
Vaccine duration of
protection = 20 years
29 % (81,490) 34 % (95,540)
Vaccine duration of
protection = 30 years
30 % (84,300) 39 % (109,590)
VE Vaccine efficacy
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(CC directly prevented by the girls vaccination + the CC
indirectly prevented by boys vaccination). The change in
vaccine efficacy would therefore not modify the coverage
in the catch-up programme under which the vaccination
of boys would prevent more CC than the catch-up of
girls. As a result, a lower vaccine efficacy would lead to
a proportional decrease in both the boys and the catch-
up vaccination.
From this modelling exercise, the adoption of boys
vaccination could result in the prevention of more CC
cases than adding catch-up female cohorts only if low
vaccination coverage is reached in girls (catch-up or pri-
mary vaccination cohort). This should however imply a
maintained high (non-overlapping) coverage in boys that
would result in the maximum CC reduction modelled in
this study. Nevertheless, if the benefit of vaccinating
boys goes beyond CC prevention among the girls not
covered in the primary cohort (important age mix
with older non-vaccinated girls), the value of a boys
vaccination could potentially be more important.
A potential limitation of our analysis could be the
assumption of a lifelong duration of protection. However,
in view of the effectiveness profile of the HPV-16/18
AS04-adjuvanted vaccine, and lacking any forecast on its
possible decay, this assumption might be reasonable [39].
Nevertheless, the sensitivity analysis conducted on the
vaccine duration of protection confirmed the results of
the base case.
We also assumed that the maximum reduction in CC
cases subsequent to the extension of HPV vaccination to
11-year-old boys would correspond to the maximum ex-
pected reduction in CC cases of non-vaccinated 11-year-
old girls as if they were all vaccinated. Such assumption
does not account for a possible more extended impact in
case vaccinated males had frequent sexual contacts with
older unvaccinated females. Nevertheless, such effect, al-
though possible, would most probably be negligible
compared to the overall impact on females of the same
age.
The results of this analysis are based on a simplified
evaluation compared with evaluation made with dynamic
models. However, they correlate with data obtained from
other previous studies based on more complex published
dynamic models [22, 40–52]. These studies have all esti-
mated a lower Incremental Cost-Effectiveness Ratio
(ICER) for girls-only vaccination compared with girls-
and-boys vaccination, the latter being not cost-effective
in most cases. They also estimated that the vaccination of
boys would become cost-effective for low vaccination
coverage on the condition, for example, of a low vaccine
price. The effect of vaccine price was however not assessed
in the current evaluation. The advantage in our study is
that it allows for adaptation to countries with less extensive
input data than the ones needed for a dynamic model, and
to be transparent about the model input and output. In the
absence of the data and computer power needed to run a
dynamic model, the approach used in the current evalu-
ation provide an alternative for countries willing to com-
pare alternative vaccination strategies.
Conclusions
Our analysis shows that HPV vaccination of 11-year-old
boys might have limited benefits on CC incidence. It
would be relevant only if female HPV vaccination cover-
age related to primary immunisation target cohort is
low. Increasing that female coverage would be a more
efficient strategy than including male vaccination to re-
duce the overall health burden of CC in the population.
Therefore, in Italy, where the HPV vaccination coverage
of the primary target population (11-year-old girls) is
about 69 % in the 1997 and 1998 birth cohorts, extend-
ing vaccination to more girls (females of the primary tar-
get cohort and/or older girls) instead of adding boys
immunisation is predicted to maximise the number of
CC cases prevented under a fixed limited additional
budget.
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